CurrentcareoregonPolicy N/A

Desmopressin prior authorization

Customize your policy alerts

Sign up for all careoregon policy alerts

Know when careoregon releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Defines prior authorization requirements for desmopressin products (nasal spray and nasal solution) for members of CareOregon; governs coverage criteria and approval lengths for specified diagnoses.

Policy Summary

Payercareoregon

PolicyDesmopressin prior authorization

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateJul 1, 2026

Next Review DateN/A

Key ActionObtain prior authorization and document the specific desmopressin product and the diagnosis when requesting approval.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Lifetimestandard approval length

0.01% / 1.5 mg/mLlisted desmopressin formulations

Hem A; VWD 1 & 2explicit covered diagnoses

Coverage criteria

Initial Coverage Criteria

Covered when ALL of the following are met

Desmopressin product: Request is for generic desmopressin 0.01% nasal spray OR generic desmopressin 1.5 mg/mL nasal solution

Covered diagnoses: Diagnosis is Hemophilia A OR Von Willebrand disease type 1 OR Von Willebrand disease type 2

Approval length: Lifetime (through 12/31/2039)

Coverage is limited to requests for generic desmopressin 0.01% nasal spray or generic desmopressin 1.5 mg/mL nasal solution when prescribed for one of the listed diagnoses. The only covered indications specified are Hemophilia A, Von Willebrand disease type 1, and Von Willebrand disease type 2.

The policy does not enumerate additional specific exclusions or conditions labeled as not medically necessary. In practice, any use that does not meet the listed product and diagnosis criteria above is outside the scope of coverage under this guideline.

Policy Summary

Payercareoregon

PolicyDesmopressin prior authorization

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateJul 1, 2026

Next Review DateN/A

Key ActionObtain prior authorization and document the specific desmopressin product and the diagnosis when requesting approval.

SourceLink

On This Page

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentcareoregonPolicy N/A

Desmopressin prior authorization

Customize your policy alerts

Sign up for all careoregon policy alerts

Know when careoregon releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Defines prior authorization requirements for desmopressin products (nasal spray and nasal solution) for members of CareOregon; governs coverage criteria and approval lengths for specified diagnoses.

Policy Summary

Payercareoregon

PolicyDesmopressin prior authorization

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateJul 1, 2026

Next Review DateN/A

Key ActionObtain prior authorization and document the specific desmopressin product and the diagnosis when requesting approval.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Lifetimestandard approval length

0.01% / 1.5 mg/mLlisted desmopressin formulations

Hem A; VWD 1 & 2explicit covered diagnoses

Coverage criteria

Initial Coverage Criteria

Covered when ALL of the following are met

Desmopressin product: Request is for generic desmopressin 0.01% nasal spray OR generic desmopressin 1.5 mg/mL nasal solution

Covered diagnoses: Diagnosis is Hemophilia A OR Von Willebrand disease type 1 OR Von Willebrand disease type 2

Approval length: Lifetime (through 12/31/2039)

Policy Summary

Payercareoregon

PolicyDesmopressin prior authorization

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateJul 1, 2026

Next Review DateN/A

Key ActionObtain prior authorization and document the specific desmopressin product and the diagnosis when requesting approval.

SourceLink

On This Page

Provider actions and requirements

Prior Authorization

Prior authorization required; approvals = Lifetime

Prior authorization is required for the listed desmopressin indications; when approved, authorizations are issued for a lifetime through 12/31/2039.

Step Therapy

No step therapy required

No step therapy requirements are specified in this guideline for the listed desmopressin products.

Documentation Required

Document product and diagnosis on PA request

When requesting prior authorization, document the specific desmopressin product formulation and the member’s diagnosis (e.g., generic desmopressin 0.01% nasal spray or generic desmopressin 1.5 mg/mL nasal solution for Hemophilia A or Von Willebrand disease type 1 or 2).

Denial Risk

Prior authorization required for listed desmopressin products

Prior authorization must be obtained for the desmopressin products and indications listed in this guideline; requests without PA may be denied.

Background

Desmopressin is included in the guideline as two intranasal formulations: generic desmopressin 0.01% nasal spray and generic desmopressin 1.5 mg/mL nasal solution. The policy frames these products for treatment of bleeding disorders and specifically lists their use for Hemophilia A and Von Willebrand disease types 1 and 2. The document focuses on prior authorization and approval duration for these formulations rather than on detailed clinical management.

Initial therapy

Initial Therapy

Initial authorization

Product and diagnosis: Request is for one of the specified desmopressin formulations (generic desmopressin 0.01% nasal spray or generic desmopressin 1.5 mg/mL nasal solution) AND the diagnosis is Hemophilia A, Von Willebrand disease type 1, or Von Willebrand disease type 2

Approval duration: If criteria are met, approval length is Lifetime (through 12/31/2039)

Continuation and renewal

Continuation Therapy

Continuation/renewal information

Continuation approval: Approvals for the listed desmopressin products and covered diagnoses are issued for a lifetime (through 12/31/2039)

Desmopressin prior authorization

Sign up for all careoregon policy alerts

Coverage criteria

Desmopressin prior authorization

Sign up for all careoregon policy alerts

Coverage criteria

Coding

Provider actions and requirements

Background

Definitions and formulations

Initial therapy

Continuation and renewal

Step therapy